Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 11 Sep 2024
Reviewer's report:
This paper systematically identified a signature of FA-related genes in patients with HCC using
WGCNA and predicted a diagnostic and prognostic model to establish the relationship between
FA metabolism and HCC. Finally, the expression level of the selected gene of SLC22A1
were verified in two HCC cell lines. The following concerns should be clarified before further
consideration:
1. There are some errors in grammar and spelling, such as "foetal bovine serum ", " utilised,
generalised and personalised etc.". It would be more readable if revising it.
2. Is there any published evidence supporting the results that SLC22A1 is associated with FAs
metabolism in HCC? Could you clarify the rationale for selecting SLC22A1? These insights
should be addressed in the introduction section.
3. Why was the Random Forest model used to identify five genes that do not overlap with the
four genes included in the risk score formula? Additionally, what is the significance of the newly
identified gene, CYS2?
4. Please explain how Weighted Gene Co-expression Network Analysis can be utilized to verify
the adequacy of the model in supporting the stated hypothesis?
5. Given the relationship between FAs metabolism and HCC, could you explain the rationale
behind choosing the SNU-449 and SNU398 cell lines to verify the expression levels of
SLC22A1? This explanation would be beneficial in the discussion section.
Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 11 Sep 2024
Reviewer's report:
This paper systematically identified a signature of FA-related genes in patients with HCC using
WGCNA and predicted a diagnostic and prognostic model to establish the relationship between
FA metabolism and HCC. Finally, the expression level of the selected gene of SLC22A1
were verified in two HCC cell lines. The following concerns should be clarified before further
consideration:
1. There are some errors in grammar and spelling, such as "foetal bovine serum ", " utilised,
generalised and personalised etc.". It would be more readable if revising it.
2. Is there any published evidence supporting the results that SLC22A1 is associated with FAs
metabolism in HCC? Could you clarify the rationale for selecting SLC22A1? These insights
should be addressed in the introduction section.
3. Why was the Random Forest model used to identify five genes that do not overlap with the
four genes included in the risk score formula? Additionally, what is the significance of the newly
identified gene, CYS2?
4. Please explain how Weighted Gene Co-expression Network Analysis can be utilized to verify
the adequacy of the model in supporting the stated hypothesis?
5. Given the relationship between FAs metabolism and HCC, could you explain the rationale
behind choosing the SNU-449 and SNU398 cell lines to verify the expression levels of
SLC22A1? This explanation would be beneficial in the discussion section.
Please review this paper.
user
Title: Investigating the Diagnostic and Prognostic Significance of Genes Related to Fatty Acid
Metabolism in Hepatocellular Carcinoma
Version: 3 Date: 11 Sep 2024
Reviewer's report:
This paper systematically identified a signature of FA-related genes in patients with HCC using
WGCNA and predicted a diagnostic and prognostic model to establish the relationship between
FA metabolism and HCC. Finally, the expression level of the selected gene of SLC22A1
were verified in two HCC cell lines. The following concerns should be clarified before further
consideration:
1. There are some errors in grammar and spelling, such as "foetal bovine serum ", " utilised,
generalised and personalised etc.". It would be more readable if revising it.
2. Is there any published evidence supporting the results that SLC22A1 is associated with FAs
metabolism in HCC? Could you clarify the rationale for selecting SLC22A1? These insights
should be addressed in the introduction section.
3. Why was the Random Forest model used to identify five genes that do not overlap with the
four genes included in the risk score formula? Additionally, what is the significance of the newly
identified gene, CYS2?
4. Please explain how Weighted Gene Co-expression Network Analysis can be utilized to verify
the adequacy of the model in supporting the stated hypothesis?
5. Given the relationship between FAs metabolism and HCC, could you explain the rationale
behind choosing the SNU-449 and SNU398 cell lines to verify the expression levels of
SLC22A1? This explanation would be beneficial in the discussion section.
assistant